Global Clinical Trial Partners taps AG Mednet for endpoint adjudication platform

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: Clinical trial, adjudication, end-to-end

Global Clinical Trial Partners selected AG Mednet’s cloud-based Judi platform to deliver its single-vendor endpoint adjudication services.

Judi is a software as service (SaaS) platform built to manage end-to-end clinical event and endpoint workflows. Global Clinical Trial Partners (GCTP) selected Judi to focus on the management of clinical event committees (CECs).

Mark Petrie a professor serving on the board of GCTP told us the partnership will mean a lot for the company’s growth and development, but was also a choice made due to both company’s missions. “In AG Mednet, GCTP has found an industry partner with a similar philosophy of quality, reliability and adaptability,” ​Petrie said.

Abraham Gutman CEO and president of AG Mednet told us that the partnership with GCTP was an easy choice because of the significant expertise and management GCTP has shown.

GCTP provides endpoint adjudication for clinical trials alongside its clinical trial consultancy. “Judi was the obvious choice for us it stood out as the industry-leading solution for endpoint adjudication due to its ability to adapt to the customer needs, whilst allowing clients to remain on budget. The user interface makes life easy for both investigators and adjudicators,” ​Petrie explained.

According to AG Mednet, GTCP has been providing services for more than 25 years on various projects. 

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars